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Abstract
Objective—HLA-B27 forms misfolded heavy chain dimers, which may predispose individuals to 
inflammatory arthritis by inducing endoplasmic reticulum (ER) stress and the unfolded protein 
response (UPR). We wanted to define the role of the UPR induced ER associated degradation 
(ERAD) pathway in the disposal of HLA-B27 dimeric conformers.
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Methods—HeLa cell lines expressing only two copies of a carboxy terminally Sv5 tagged HLA-
B27 were generated. The ER stress induced EDEM1 protein was over expressed by transfection 
and dimer levels monitored by immunoblotting. EDEM1, the UPR associated transcription factor 
XBP-1, the E3 ubiquitin ligase HRD1, the degradation associated derlin 1 and 2 proteins were 
inhibited by either short hairpin RNA or dominant negative mutants. The UPR associated ERAD 
of HLA-B27 was confirmed using ER stress inducing pharamacological agents in kinetic and 
pulse chase assays.
Results—We demonstrate that UPR induced machinery can target HLA-B27 dimers, and that 
dimer formation can be controlled by alterations to expression levels of components of the UPR 
induced ERAD pathway. HLA-B27 dimers and misfolded MHC class I monomeric molecules 
were detected bound to EDEM1, with overexpression of EDEM1 inhibiting HLA-B27 dimer 
formation. EDEM1 inhibition resulted in upregulation of HLA-B27 dimers, whilst UPR induced 
ERAD of dimers was prevented in the absence of EDEM1. HLA-B27 dimer formation was also 
enhanced in the absence of XBP-1, HRD1 and derlin1/2.
Conclusion—The UPR ERAD pathway as described here can dispose of HLA-B27 dimers and 
presents a potential novel therapeutic target for the modulation of HLA-B27 associated 
inflammatory disease.
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HLA-B27 is strongly associated with a group of inflammatory arthritic conditions known as 
the spondyloarthropathies, with Ankylosing Spondyltis (AS) representing the prototypical 
presentation (1, 2). Up to 90–95% of patients with AS express HLA-B27 but despite this 
genetic association being known for almost four decades, the disease mechanism remains 
poorly understood. Genome-wide genetic screens have identified a number of other genes 
contributing to AS, but none have yet fully explained the disease process (3). One current 
theory linking HLA-B27 to AS involves the predisposition of HLA-B27 heavy chain to 
misfold and form non-native heavy chain dimeric structures (4). HLA-B27 dimers have been 
correlated with disease in the rat model for SpA (5). Dimers may interact aberrantly with 
immune receptors at the cell surface, or act within the environment of the endoplasmic 
reticulum (ER) to induce cellular stress responses, potentially leading to the onset of pro-
inflammatory responses (6, 7).
MHC class I molecules present unique protein folding challenges to the ER quality control 
machinery and HLA-B27 is particularly prone to misfolding forming disulfided bonded 
dimers (8). Misfolding proteins within the ER can induce the Unfolded Protein Response 
(UPR), which is a cellular stress response initiating transcriptional changes whose function 
is to restore ER homeostasis (9, 10). There are three main effector molecules of the UPR, the 
ATF6 transcription factor and the two kinases IRE1 and PERK, which reside within the ER 
and all are maintained in an inactive state by the ER resident chaperone Immunoglobulin 
Binding Protein (BiP) (10–12). One of the most potent transcriptional changes induced by 
the UPR follows the oligomerisation and autophosphorylation of IRE1. Phosphorylated 
IRE1 can splice the cytosolically located X-box binding protein 1 (XBP-1) mRNA by 
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excising a 26 nucleotide intronic sequence, generating the XBP-1 spliced(s) transcription 
factor (13). XBP-1s can activate chaperones to enhance both cellular folding capacity and/or 
proteins involved in degradation of misfolding substrates (14).
ER degradation-enhancing α-mannosidase-like protein 1 (EDEM1) was originally cloned as 
an ER stress induced gene (15), which is targeted by XBP-1s (14). EDEM1 overexpression 
studies have demonstrated a role in the degradation of misfolded proteins. EDEM1 is 
thought to handle misfolded proteins in concert with the ER chaperone calnexin and the 
UPR induced XBP-1 target E3 ubiquitin ligase HRD-1-SEL1 complex (16–18). Together 
with the E2-ubiquitin conjugating enzyme UBE2J1 they were shown to participate in the 
degradation of misfolded MHC class I heavy chains at steady state (19). Very recently, a 
role for EDEM1 in the MHC class I pathway has also been demonstrated (20), although its 
interaction with HLA-B27 was not investigated.
In this current study we demonstrate that EDEM1 participates in the degradation of HLA-
B27 dimers under ER stress conditions. This degradation pathway requires XBP-1 and 
HRD1. Significantly, our data highlight the ER stress induced ERAD pathway as a potential 
route for therapeutic intervention in HLA-B27 associated diseases.
Materials and Methods
Cell lines and antibodies
Cells were maintained in DMEM, supplemented with 10% FBS (Globepharm), penicillin/
streptomycin (D10 media) and maintained in a 5% CO2 37°C incubator. The Invitrogen Flp-
In™ system was used to generate isogenic HeLa lines stably expressing HLA class I 
constructs. HeLa cells with two integrated copies of the pFRT/lacZeo plasmid were 
identified by Southern blot analysis. Clone H2Z, was β-galactosidase positive and Zeocin™ 
resistant. HLA class I constructs for expression were cloned into the pEF5/FRT/V5-D-
TOPO® vector. The relevant FRT-containing expression plasmid was co-transfected 
together with the Flp recombinase expressing plasmid pOG44, into H2Z cells and selected 
using hygromycin B. Recombinants were identified by the lack of β-galactosidase 
expression and Zeocin™ sensitivity, thus generating stable isogenic lines containing two 
copies of HLA class I expression constructs driven by the human EF-1α promoter or CMV 
promotor.
The following antibodies were used: anti-V5 (pK) (Serotec), anti-FLAG, anti-EDEM1 and 
anti-rabbit monoclonal HRP (Sigma) and goat anti-mouse horseradish peroxidase (DAKO).
Transient transfections
HeLa and 293T cells were plated at 1 × 105 and 5 × 105 cells/well respectively and 
transfected with cDNA expression constructs and JetPrime PEI (PolyPlus Transfection) or 
Fugene respectively according to manufacturers’ recommended conditions.
Immunoprecipitation analysis
For EDEM1 immunoprecipitation experiments, HeLa cells expressing HLA-B*27:05 were 
transfected with a FLAG tagged EDEM1, incubated with 20mM NEM/PBS pH7.4 and lysed 
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in 1% digitonin lysis buffer, immunoprecipitated with anti-FLAG antibody and washed in 
1% digitonin buffer. For analysis of EDEM1 binding to MHC class I molecules, 293T cells 
co-transfected with EDEM1-FLAG and HLA class I molecules were treated in 20mM NEM, 
lysed in 1% NP40 lysis buffer and immunoprecipitated with anti-FLAG antibody.
Immunoblotting
Samples were resolved by non-reducing SDS-PAGE, transferred onto nitrocellulose (BA85, 
Schleicher and Scheull), blocked for 1 hr with 5% skimmed milk powder in PBS/0.1% 
Tween, followed by incubation with antibodies. Images were revealed by 
chemiluminescence using Supersignal Femto reagents (Pierce).
Knockdown analysis
For XBP-1 knockdown, transductions with shRNA-expressing lentiviral vector (pCSBX/
pIG) targeting XBP-1 (shXBP-1) were as previously described (21). An equivalent control 
vector expressing an shRNA targeting luciferase (shLuc) was generated using the same 
methodology. HEK 293T cells were transfected with p8.91, pMDG, and the shRNA-
expressing lentiviral vector genome using FuGENE-6. Samples showing high levels of viral 
transduction (>90% GFP+ by FACS) were processed and immunoblotted. For HRD1 and 
EDEM1 knockdowns, previously described 19mers matching HRD1 (19) or EDEM1 
cDNAs (22) were incorporated into DNA oligos that were cloned into pSIREN-RetroQ 
(Clontech) shRNA expression vector and sequence verified. HEK 293Ts were transfected 
with plasmids encoding Moloney MLV gag-pol (pCMVi), VSV-G env (pMDG) and 
pSIREN-RetroQ-shHRD1 or shEDEM1 to make pseudotyped virus-like particles. 
Supernatants were harvested at 48hrs post-transfection.
Chemical inhibitor assays
HeLa cells expressing HLA-B*27:05 were incubated at 1 × 105 cells/well with varying 
concentrations of kifuensine (Calbiochem) or DMSO as controls and harvested 18 hrs later. 
ER induction and dimer half life assays; HeLa.B27 cells were incubated with varying 
concentrations of TUN, TPG and MG132 for ER stress studies or 50μM cycloheximide for 
half life analyses. Equal number of cells were harvested, NEM treated and lysed in 1% 
NP40 lysis buffer. Protein loading was normalised by cell number or MTT assay.
Monocyte-derived dendritic cells and quantitation
After full local ethical committee review, and informed consent, peripheral blood 
mononuclear cells were isolated by centrifugation of whole blood over Histopaque (Sigma, 
Poole, UK). Two hour plastic adherent monocytes (in RPMI, 10% FBS) were cultured with 
50ng/ml interleukin 4 (IL-4) and 50ng/ml granulocyte macrophage-colony stimulating factor 
(GM-CSF) (R&D Systems, Abingdon, UK). DCs were allowed to differentiate for 5 days, 
before treatment with 100ng/ml lipopolysaccharide (LPS) (Sigma, Poole, UK). Cell lysates 
were analysed by SDS-PAGE and immunoblotted for MHC class I heavy chain with HC10, 
and for HRD1, and developed with Supersignal Femto chemiluminescent reagents. HRD1 
and B27D values were generated from the Integrated Density in Image J. All values were 
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then normalised to β-actin. For quantitation of HLA-B alleles lysates were analysed for 
HC10 reactivity and values generated as described.
Pulse chase analysis
Cells were serum starved for 15 mins and labeled with 35S cys/met 300μCi for 15 mins. 
Radiolabel was removed and cells resuspended in D10. For ER stress or pharmacological 
treatment, drugs were added at the point of chase. Equal number of cells were removed at 
each time point, treated with 20mM NEM pH7.4 on ice for 20 mins, lysed in 1% NP40 and 
immunoprecipitated for MHC class I. Prior to resolution on non-reducing SDS-PAGE, 
samples were treated with endoH for 1hr at 37°C.
Results
EDEM1 can associate with aberrant MHC class I conformers
To determine the role of EDEM1 in the processing of HLA-B27 dimers, we employed 
isogenic HeLa cells expressing two copies of either Sv5 C-terminally tagged HLA-B27 
(HeLa-B27.Sv5) or HLA-B*35:01 (-B35) under the control of the E1Fα promoter, the latter 
as a control HLA-B allele which does not form disulfide linked dimers.
Flow cytometric analysis of HeLa.B27.Sv5 and -B35.Sv5 with ME1 and 4E antibodies 
respectively demonstrated efficient cell surface expression of these MHC class I molecules 
(Fig 1A, top and bottom left panels), whilst W632 staining demonstrated that all lines 
expressed endogenous MHC class I molecules. We assessed the amount of HLA-B proteins 
expressed by HeLa compared to HeLa.B27.Sv5 using immunoblotting with HC10. 
Quantitation revealed approximately twice as much HLA-B expression in HeLa.B27.Sv5 
compared to wild type HeLa cells, in keeping with the additional two copies of HLA-B27 
(Fig. 1B). We previously showed that HLA-B27 exhibits slow maturation kinetics (23) and 
pulse chase analysis of HeLa.B27.Sv5 confirmed the slow maturation kinetics compared to 
HLA-B35 as demonstrated by the acquisition of endoglycosidase H (endoH) resistant 
material within 2hrs (Fig. 1C, second and third panels). Pulse chase analysis of endogenous 
W632 reactive MHC class I molecules in wildtype HeLa (Fig. 1C top panel) and the 
analysis of HLA-B35, demonstrated that MHC molecules can be processed efficiently and 
rapidly by HeLa cells and that the slow kinetics of HLA-B27 are independent of cell line 
expression.
To determine the role of EDEM1 in the processing of HLA-B27 dimers, we both enhanced 
and inhibited EDEM1 expression. The HeLa-B27.Sv5 line expresses three distinct dimer 
populations (arrows 1–3) which we have previously determined corresponds to dimers in 
different redox states (24). Overexpression of EDEM1 resulted in a modest reduction in the 
levels of all HLA-B27 dimer populations (Fig. 2A, arrows 1–3). Depletion of EDEM1 
expression (Fig. 2B, left panel) led to enhancement in all three dimer populations (Fig. 2B, 
right top panel). As both of these detectable differences in dimer levels were made at steady 
state, we then induced ER stress in the absence of EDEM1 using thapsigargin (TPG). 
Immunoblotting revealed that HLA-B27 dimers were more abundant in EDEM1 depleted 
cells (Fig. 2B, right bottom panel).
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To further verify that EDEM1 can participate in the degradation of aberrant HLA-B27 
dimers we employed a pharmacological approach. HLA-B27 dimers were enhanced after 
treatment with kifuensine (KIF) which inhibits ERAD and the interaction of EDEM1 with 
the SEL1-HRD1 degradation complex (18, 25, 26) (Fig. 2C, top left panel). In addition, the 
dimer complexes displayed a small increase in Mw, characteristic of the retention of high 
mannose groups due to the inhibition of class I α-mannosidase activity (Fig. 2C, Insert 1 
enlarged image of dimers). The monomers for both HLA-B27 and –B35 were also resolved 
as two closely migrating bands in the presence of KIF, which may represent a mannosylated 
heavy chain and/or intermediates of HLA heavy chains prior to ERAD (Fig. 2C, Insert 2 
arrows, enlarged image of monomeric heavy chains). KIF treatment could potentially affect 
dimer formation by altering the maturation rate of HLA-B27. However, pulse chase analysis 
in the presence of KIF revealed no alteration in HLA-B27 maturation rates (Fig. 2C, bottom 
left panel).
To determine whether EDEM1 can directly associate with different forms of HLA-B27, 
EDEM1-FLAG cDNA was either transfected into HeLa-B27.Sv5 cells, or co-transfected 
with HLA-B*27:05 cDNA into HeLa cells. Following immunoprecipitation of EDEM1, 
immunoblotting for HLA-B27 with antibody HC10, demonstrated the preferential 
association of HLA-B27 dimers compared to monomeric HLA-B27 (Fig. 2D, top panel). 
These data suggest that EDEM1 can both associate with MHC class I dimeric heavy chains 
and modulate their levels.
Misfolded MHC class I heavy chains interact with EDEM1 in a glycan independent manner
To address whether EDEM1 can associate directly with misfolded monomeric heavy chains, 
we used a cell based binding assay. 293T cells were co-transfected with EDEM1-FLAG and 
a C-terminally Sv5 tagged wild type HLA-B*27:05 or with similarly tagged misfolding 
HLA-B27 molecules which have had the conserved structural cysteines of the α2 domain 
mutated to serines at position 101 (C101S) or 164 (C164S). We employed the structural 
HLA-B27.C101S mutant as the monomer misfolds but retains the ability to extensively 
dimerise and the C164S mutant exhibits enhanced levels of misfolded monomer with a 
reduced ability to dimerise (23). Therefore by using these mutants we could determine 
whether EDEM1 associates with dimeric and/or monomeric conformations. 24hrs post-
transfection, 293T cells were harvested, treated in 20mM NEM and lysed in 1% NP40. 
Lysates were immunoprecipitated for EDEM1 using an anti-FLAG antibody and resolved by 
reducing SDS-PAGE. Immunoblotting for HLA-B27 with the anti-Sv5 pK antibody 
indicated that WT HLA-B*27:05 and the C101S and C164S mutants could be co-
immunoprecipitated with EDEM1 (Fig. 3A). When resolved under non-reducing conditions, 
fewer monomeric wildtype HLA-B27 heavy chains interacted with EDEM1. It is likely that 
this pool would contain both correctly and misfolded monomers, whereas both C101S and 
C164S monomer heavy chain pools would all be classified as misfolded (Fig. 3B). 
Interestingly, C101S predominantly associated as a dimer with EDEM1, whilst C164S 
demonstrated an altered dimeric conformation, but could associate with EDEM1 both as a 
monomer and dimer (Fig. 3B).
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To determine whether the EDEM1 mannosidase-like domain was important in HLA-B27 
heavy chain recognition we employed a series of EDEM1 mutants whose acidic active site 
residues within the mannosidase-like domain have been mutated to neutral amino acids 
which abolish glycan dependent substrate binding; E225Q, D370N or E493Q. In addition 
we also employed a triple mutant of this domain (TM, E225Q/D370N/E493Q). To further 
address the requirement of glycan binding, we employed a glycosylation site deficient 
mutant of HLA-B27 (N86K). Using our cell based binding assay we co-expressed EDEM1 
WT or the four EDEM1 mutants with HLA-B27 or the B27.N86K mutant. Cells were NEM 
treated, lysed in 1% NP40 and immunoprecipitated for EDEM1. Immunoblotting for MHC 
class I heavy chains demonstrated both WT and N86K HLA-B27 could be co-
immunoprecipitated with all EDEM1 mutants (Fig. 3C).
HLA-B27 dimers can be ER resident and expressed at the cell surface. To determine which 
pool of dimers were associated with EDEM1, we subjected the EDEM1-associated HLA-
B27 molecules to digestion with endoH. Immunoblotting revealed that following endoH 
digestion, the dimeric population associating with EDEM1 exhibited an apparent lower Mw, 
correlating with the removal of glycans from ER resident dimers (Fig. 3D, right panel). 
Furthermore, we could also detect monomeric HLA-B27 under these overexpression 
experimental conditions, which were also susceptible to endoH digestion (Fig. 3D, right 
panel).
Therefore the EDEM1-MHC class I interaction is not dependent on glycosylation of the 
substrate or the glycan binding site of EDEM1, with EDEM1 binding ER resident dimers 
and misfolding monomeric heavy chains.
HLA-B27 dimer ERAD requires the XBP-1 pathway, HRD1 and can use Derlin 1 and 2
As EDEM1 is a target gene for the potent UPR XBP-1s transcription factor (14, 27) we 
predicted that heavy chain dimer degradation would require an intact XBP-1 pathway. We 
transduced HeLa.B27.Sv5 with a lentivirus expressing a short hairpin (sh) RNA targeting 
XBP-1. Immunoblotting revealed that in the absence of XBP-1, HLA-B27 dimers are more 
prevalent (Fig. 4A, left panel and enlarged insert panel).
EDEM1 and HRD1 are targets for XBP-1s induction (14, 27) and EDEM1 can associate 
with the HRD1-SEL1 degradation complex (18), we therefore wanted to confirm the role of 
HRD1 in HLA-B27 dimer degradation. We hypothesized that inhibition of HRD1 
expression should prevent ERAD of HLA-B27 dimers. HeLa-B27.Sv5 cells were infected 
with a retrovirus expressing an shRNA construct targeting HRD-1. Immunoblotting for 
HLA-B27 dimers revealed a large accumulation of dimers and larger aggregates (Fig. 4A, 
right panel). We then wanted to determine how inhibiting XBP-1 affected HRD1 and 
EDEM1 expression. XBP-1 inhibition led to a reduction in steady state levels of HRD1 but 
did not greatly affect EDEM1. We then subjected HeLa cells that were either mock 
transduced or had XBP-1 inhibited with the ER stress inducing agent TPG. HRD1 and 
EDEM1 could both be induced by increasing concentrations of TPG, however in the 
absence of XBP-1, neither of these proteins could be significantly induced (Fig. 4B). 
Therefore, inhibiting XBP-1 can prevent the induction of EDEM1 and HRD1 under stress 
conditions.
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To determine the physiological significance of the above pathway for HLA-B27 dimer 
degradation, we analysed HLA-B27 dimer and HRD1 levels in cells from HLA-B27 positive 
AS patients. Monocyte derived dendritic cells from peripheral blood were stimulated with 
LPS and MHC class I dimer and HRD1 levels analysed by immunoblotting. Intriguingly, 
HRD1 levels were consistently higher in patient derived DC compared to HLA-B27 positive 
healthy controls (Fig. 4C) suggesting HRD1 may regulate HLA-B27 dimer levels in AS 
patient cells.
The derlin proteins have been postulated to be part of putative degradation pores and act as 
adaptors for ERAD substrates (28). Derlin 1 is involved in US11 mediated retrotranslocation 
of monomeric MHC class I molecules (29), whilst derlin 2 links EDEM1 with the ERAD 
p97 component. Furthermore derlins 1–3 can be induced by ER stress (30). As derlin 1 has a 
role in MHC class I ERAD and derlin 2 has been demonstrated to associate with EDEM1 we 
therefore wanted to determine whether HLA-B27 dimer degradation could be affected by 
derlin 1 and/or 2. We employed derlin 1 and 2 Green Fluorescent Protein (GFP) fusion 
proteins (Fig. 4D, left panel) which act as dominant negative proteins for their respective 
products (29). The inhibition of derlin 1 and 2 by their respective dominant negative proteins 
resulted in enhanced dimers (Fig. 4D, middle and right panel). Thus HLA-B27 dimers can 
be targeted for degradation via an XBP-1 dependent pathway and their degradation involves 
the E3 ubiquitin ligase HRD1 and the putative adaptor proteins derlins 1 and/or 2.
HLA-B27 heavy chain dimers are long lived
HLA-B27 dimers have been postulated to be pathogenic and participate in inflammatory 
arthritic disease (5). However, the duration of HLA-B27 dimers has been poorly analysed, 
therefore we initially wanted to determine the half life of HLA-B27 dimers. HLA-B27 
HC10 reactive dimers have been reported to have a half life of approximately 2hrs (31), 
however using our controlled expression system of HLA-B27 we could determine the 
duration of all populations of dimers.
Using HeLa.B27 cells, we metabolically labelled the cells for 15 mins with 35S cys/met 
before chasing for 0, 2, 4, 6 and 8hrs and immunoprecipitating with the anti-Sv5 pK 
antibody. Pulse chase analysis revealed that dimers were long lived and evident up to 8 hrs 
(Fig. 5A). To further assess the half life of HLA-B27 dimers, we treated cells with the 
protein synthesis inhibitor cyclohexamide (50μM) and assessed dimer levels by 
immunoblotting. Again this analysis revealed that HLA-B27 dimers were extremely long 
lived with detectable levels remaining 18hrs after cyclohexamide treatment (Fig. 5B). 
Therefore, at steady state levels HLA-B27 dimers exhibit a prolonged lifetime and appear to 
be resistant to steady state degradation pathways.
ERAD of HLA-B27 dimers is enhanced by pharmacological induction of the UPR
Our data indicate that induction of ER stress could aid in dimer removal and could 
potentially be employed as a therapeutic intervention strategy. If EDEM1 and/or other 
proteins upregulated during ER stress are involved in ERAD of HLA-B27 dimers, we 
hypothesised that induction of the UPR should enhance the removal of HLA-B27 dimers. To 
test this HeLa-B27.Sv5 cells were incubated with pharmacological agents known to induce 
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the UPR, such as tunicamycin (TUN), TPG and MG132 (32). Immunoblotting revealed 
significantly fewer HLA-B27 dimers, suggesting that ER stress-induced ERAD was 
regulating dimer levels (Fig. 6A).
We then determined whether ER stress reduced the half life of dimers by performing kinetic 
and pulse chase analyses. A kinetic study of the effects of these drugs revealed initial 
enhanced dimerisation, as might be expected from their ability to inhibit normal folding 
processes, but this was followed by dimer disappearance (Fig. 6B–C and unpublished 
observations). For pulse chase analysis, cells were metabolically labelled and at the point of 
chase, cells were incubated with TUN (Fig. 6C, top panel). Following such treatment, 
dimers were indeed degraded far more rapidly disappearing within 8–12hrs post treatment 
(Fig. 6C bottom panel, compare top with middle panel). Previously, we demonstrated that 
changes within the 1–2hrs of maturation can affect the ability of MHC class I molecules to 
dimerise (23). It was possible that dimer levels could be modulated by the effects of these 
drugs on the maturation rates of the HLA-B27 monomer. However, pulse chase analysis in 
the presence of TPG and TUN did not reveal any alterations to the maturation phenotype 
following ER stress induction during the first 4hrs. However TUN appeared to enhanced the 
maturation rate markedly, whilst TPG had little if any effect (Fig. 6D, compare panels 1–3). 
Therefore, induction of ER stress, using a pharmacological approach can modulate levels of 
aberrant misfolded MHC class I molecules.
Discussion
We have defined a role for EDEM1 in the degradation pathway of HLA-B27 dimeric 
molecules. The XBP-1 induced ERAD of HLA-B27 dimers involves EDEM1, the E3 
ubiquitin ligase HRD1 and the adaptor proteins derlin-1 and –2 (Fig. 4). EDEM1 shows 
specific affinity for HLA-B27 dimers as well as binding to misfolded monomers (Figs 2&3).
The induction of ERAD via the UPR has been demonstrated to lead to the degradation of 
misfolded proteins (33). UPR induced ERAD appears to target misfolded polypeptides in 
preference to folded monomers and this could in part be explained by the activity of 
EDEM1. How EDEM1 distinguishes such structures remains unresolved, but could involve 
interactions with calnexin and/or BiP. EDEM1 was originally proposed to act on misfolding 
substrates through its proposed mannosidase activity. However, our findings demonstrate 
that the mannosidase active site of EDEM1 is not necessary for substrate interactions (Fig. 
3C). Our study suggests that the glycosylation status of this substrate does not influence its 
interaction with EDEM1 (Fig. 3C). These observations are consistent with those made for 
EDEM1 interactions with the model misfolding α-1-antitrypsin null Hong Kong protein 
(18).
Our study strongly suggests that HLA-B27 dimers are long lived. Relatively little is known 
regarding the half life and duration of such aberrant conformers. It has been proposed that 
HC10 reactive dimers have a half life of approximately 2hrs (31). However, in our system 
HLA-B27 expression is controlled and employs a C-terminally tagged epitope which 
enables us to perform an unbiased analysis of dimeric populations. It is possible that dimer 
duration and expression could be affected by additional factors. Recently, ER 
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Aminopeptidase (ERAP)1, which trims MHC class I associated peptides (34) has also been 
found to be associated with AS (3). The peptide trimming activity could be altered by 
ERAP1 polymorphisms associated with AS or by increased expression levels (35), which 
could generate unstable peptides similar to those observed in ERAP1 knockout cells (36). 
An altered peptide subset could lead to MHC class I misfolding, increasing the propensity 
for HLA-B27 to dimerise and potentially overload the ERAD cell machinary. Recently, a 
poor supply of peptides was postulated to participate in the expression of cell surface HLA-
B27 dimeric conformers (37). Therefore it is entirely possible that the peptide repertoire can 
participate in the expression of aberrant ER resident or plasma membrane associated HLA-
B27 conformers.
Our findings have three potentially important implications. First, if misfolding and 
aggregation of HLA-B27 cause the associated inflammatory diseases then they could be 
targeted for therapeutic intervention in a manner similar to other protein conformational 
diseases. HRD1 activity has been implicated in such disorders (38) and our demonstration 
that HRD1 expression and possibly activity correlates with disease, suggest that this 
pathway may have an important role in how these conformers are handled in AS patients. 
Though we demonstrate that HRD1 and EDEM1 participate in the degradation of HLA-B27 
dimers and that this pathway may be activated in AS patients, it is possible that differences 
exist in these pathways when comparing ex vivo DC expressing physiological levels of 
MHC class I molecules compared to transfected cell lines, and as such will require further 
investigation. Secondly, EDEM1 and engagement of the HRD1-SEL1 complex appear to be 
the rate limiting steps in the degradation of pathogenic disulfide bonded dimers of HLA-
B27. It has previously been postulated that the resolution of disulfide bonds of HLA-B27 
homodimers determined the rate of their degradation, however at steady state these 
molecules are far more long lived and stable than originally proposed. Thirdly, the 
degradation of HLA-B27 dimers offers the potential for therapeutic targetting by 
manipulating the ER stress response and induction of the ERAD pathway. Our study 
demonstrates that the ER stress pathway can be manipulated to modulate dimer expression. 
The use of ER stress inducing drugs highlights this “proof of principle” application with 
dimers becoming less apparent following the use of such ER stress inducing drugs (Fig. 6). 
Pulse chase analysis with the drugs employed at the point of chase demonstrate that the 
heavy chain can still mature slowly and that maturation is not altered significantly to 
account for the reduced detection of dimeric HLA-B27 populations (Fig. 6D). Thus the 
effects that we observe on dimer levels by these drugs is not due to their effects on folding. 
These drugs in theory should perturb folding and as such cause an accumulation of dimers. 
However, kinetic studies demonstrate a biphasic action of these drugs with early stages (0–
8hrs) showing a brief accumulation of dimers (Fig. 6B) which then decline at later time 
points correlating with the induction of HRD1 (unpublished observations). Thus the initial 
effect of ER stress inducing drugs is to interfere with protein folding, with the accumulation 
of misfolding protein triggering ER stress pathways.
The spondyloarthropathies have been hypothesised to be disorders resulting from HLA-B27 
misfolding, with dimerisation contributing to the disease process (4,39). Understanding the 
factors that contribute to the misfolding of HLA-B27 could have an impact on future 
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therapeutic approaches. Our study suggests that modulating ER stress could offer a novel 
therapeutic intervention point. Drugs modulating ER stress responses are already under 
clinical development and testing for the treatment of multiple myelomas (40, 41). These 
could be tested and if effective repurposed for the treatement of HLA-B27 associated group 
of diseases and also other disorders associated with protein misfolding.
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AS Ankylosing Spondylitis
BiP Immunoglobulin Binding Protein
ER endoplasmic reticulum
CST casternospermine
DC dendritic cell
DMJ Deoxymannojirimycin
DNJ deoxynorjirimycin
EDEM1 ER degradation-enhancing α-mannosidase-like protein 1
ERAD ER-associated degradation pathway
ERAP ER Aminopeptidase
GFP Green fluorescent protein
HLA Human Leukocyte Antigen
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Figure 1. 
HLA-B27 expression and maturation in HeLa cells; (A) HLA-B27 and –B35 are expressed 
efficiently at the cell surface. HeLa.B27.Sv5 and –B35.Sv5 were analysed by flow 
cytometry with antibodies ME1 (top left) and 4E (bottom left) respectively. HeLa.B27, -
B35 and mock transfected control E84 express W632 reactive MHC class I molecules. (B) 
Quantitation of HLA-B alleles using HC10 antibody signal reveals approximately twice as 
much HLA-B expression in HeLa.B27.Sv5 compared to wild type HeLa cells. (C) HeLa 
cells process MHC class I molecules efficiently. Pulse chase analysis of endogenous MHC 
class I molecules using antibody W632 followed by endo H digestion reveals that MHC 
class I molecules mature within 1hr (top panel). Pulse chase of HLA-B27.Sv5 using the 
anti-Sv5 antibody pK reveals little endo H resistant material being acquired during 2 hrs of 
chase (middle panel). Control HLA-B35.Sv5 exhibit a rapid acquisition of endo H resistance 
in HeLa cells (bottom panel).
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Figure 2. 
EDEM1 modulates HLA-B27 dimers; (A) Over expression of EDEM1 can enhance HLA-
B27 dimer degradation. HeLa-B27 were transfected with EDEM1-FLAG, lysed and 
immunoblotted for MHC class I heavy chain. Arrows 1, 2 and 3 indicate HLA-B27 dimers. 
Lysates immunoblotted with anti-FLAG demonstrate EDEM1 expression. (B) shRNA 
inhibition of EDEM1 expression (left panel) in HeLa-B27 cells prevents HLA-B27 dimer 
ERAD when compared to mock transduction with a control scrambled shRNA (middle 
panel). HLA-B27 dimers are resistant to ER stress induced degradation following EDEM1 
knockdown (right panel). (C) Increasing concentrations of kifuesine (KIF) lead to enhanced 
detection of dimers as determined by immunoblotting of HeLa-B27.Sv5. Immunoblotting 
for GAPDH reveals equal loading. Insert 1 demonstrates that with increasing KIF 
concentrations the high Mw dimers exhibit small changes in Mw. Insert 2 arrows indicate 
that at 2.5 μg/ml KIF, the monomer of both HLA-B27:05 and –B*35:01 can be resolved as a 
doublet (left panel) Kifuensine does not alter the maturation rate of HLA-B27. HeLa-
B27.Sv5 were radiolabeled and chased in the presence of kifuensine or vehicle control 
DMSO (right panel). (D) HLA-B27 ER resident dimers preferentially associate with 
EDEM1 (left panel). HeLa-B27.Sv5 were transfected with EDEM1-FLAG, or HeLa cells 
were co-transfected with HLA-B27 and EDEM1-FLAG and cell lysates were 
immunoprecipitated with an anti-FLAG tag antibody and immunoblotted for class I heavy 
chain (left panel). Immunoblotting lysates with anti-FLAG from HeLa and HeLa-B27Sv5 
cells transfected with EDEM1 demonstrates equal levels of EDEM1 expression (right 
panel).
Guiliano et al. Page 16
Arthritis Rheumatol. Author manuscript; available in PMC 2015 April 16.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 3. 
EDEM1 associates with dimeric and monomeric MHC class I conformers. (A) MHC class I 
molecules are detected only when coexpressed with EDEM1. 293T cells were cotransfected 
with EDEM1 and HLA-B27.Sv5 or along with two misfolding mutants B27.C101S and 
B27.C164S. Lysates were immunoprecipitated for anti-FLAG, resolved by reducing SDS-
PAGE and immunoblotted for V5 using the pK antibody. (B) Both monomers and dimers 
can be detected in association with EDEM1. Similar immunoprecipitates were resolved by 
non-reducing SDS-PAGE and immunoblotted with pK antibody. Note that dimeric 
structures are preferentially detected in the presence of WT HLA-B27 and the C101S mutant 
(?). * denotes non-specific background band. (C) EDEM1 associates with HLA-B27 in a 
glycosylation independent manner. 293T cells were cotransfected with EDEM1, E225Q, 
D370N, E493Q or a triple mutant (TM) contaning all three mutations, along with HLA-B27 
Guiliano et al. Page 17
Arthritis Rheumatol. Author manuscript; available in PMC 2015 April 16.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
wt or a glycosylation site deficient mutant N86K. Lysates were immunoprecipitated with 
anti-FLAG, resolved by reducing SDS-PAGE and probed with pK. (D) EDEM1 was 
immunoprecipitated and endo H digested following co-transfection with HLA-B27 in 293T 
cells, followed by immunoblotting for MHC class I heavy chain.
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Figure 4. 
XBP-1, HRD1 and Derlin1/2 participate in HLA-B27 dimer degradation. (A) Degradation of 
HLA-B27 is dependent on the XBP-1 pathway. shXBP1 inhibition demonstrates enhanced 
dimerisation of HLA-B27, with Insert showing the dimers following longer exposure (left 
panel). shRNA inhibition of HRD1 expression in HeLa-B27 cells prevents HLA-B27 dimer 
ERAD when compared to mock transduction with a control shRNA (shLUC). 
Immunoblotting lysates demonstrates that HRD1 has been down regulated (right panel). 
(B) HRD1 and EDEM1 depend on XBP-1 for ER stress induction. ShRNA inhibition of 
XBP-1 does not lead to induction of HRD1 and EDEM1 following ER stress induction with 
thapsigargin (TPG) compared to shLUC mock control cells. (C) HRD1 and HC10 reactive 
HLA-B27 dimer levels were quantified in both immature (I) and mature (M) dendritic cells 
generated from HLA-B27 patients. HRD1 levels can be elevated in dendritic cells from AS 
patients. Open bars represent normalised B27 dimer (D) levels and shaded bars represent 
normalised HRD1 levels. (D) Derlin-1 and –2 can participate in HLA-B27 dimer ERAD. 
Derlin-1.GFP and Derlin-2.GFP expression following retroviral infection of HeLa cells 
expressing HLA-B27 and HLA-B35 (left panel). HeLa-B27 cells were transduced with 
Derlin-1 and -2 GFP tagged proteins, which act as dominant negative inhibitors of the 
respective Derlin activities. Immunoblotting revealed that both Derlin-1 and –2 can 
modestly enhance HLA-B27 dimer formation, leading to the enhanced detection of dimers 
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as highlighted by arrows 1, 2 and 3 (middle panel). Quantitation of the different dimer 
bands 1, 2 and 3 reveals a 2–3 fold increase in their detection when Derlin 1 and 2 activities 
are inhibited (right panel).
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Figure 5. 
Half life and UPR induced ERAD of HLA-B27 heavy chain dimers. (A) HLA-B27 dimers 
have a prolonged duration. HeLa.B27Sv5 cells were metabolically labeled, chased and 
immunopecipitated with pK antibody. HLA-B27 dimers were apparent at 8hrs of chase. (B) 
HLA-B27 dimers have a half life in excess of 16hrs. HeLa.B27Sv5 cells were treated with 
50μM cycloheximide and dimer levels detected by immunoblotting lysates resolved by non-
reducing SDS-PAGE.
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Figure 6. 
(A–D); Incubation with UPR inducing drugs leads to loss of HLA-B27 dimers. (A) 
Treatment with tunicamycin (TUN), thapsigargin (TPG) and MG132 lead to loss of HLA-
B27 dimers. (B) TUN and TPG lead to dimer disappearance after 8hrs of treatment (top left 
and right panels). ER stress drugs exhibit a biphasic effect of action. TUN and MG132 lead 
to the accumulation of dimers up to 8 hrs (left and right panels) TUN results in the 
appearance of glycan free (-CHO) forms of dimers (left). (C) Tunicamycin enhances the rate 
of dimer degradation. HLA-B27 cells were labeled with 35S cys/met and then chased in the 
presence (top panel) or absence (bottom panel) of tunicamycin (5μg/ml). Cells were chased 
for 0, 2, 4, 13, 14, 16 and 18hrs and immunoprecipitated for MHC class I heavy chain with 
the pK antibody. Dimers (D) and monomers (M) are highlighted, * denotes BiP. Note 
dimers are not apparent after 4hrs of chase (top panel). (D) The maturation rate of HLA-
B27 as determined by pulse chase analysis is not grossly affected by ER stress inducing 
drugs (TPG and TUN, panels 1–3). Endogenous MHC class I molecules expressed by HeLa 
cells can mature within 1 hr (panel 4). HLA-B35 matures rapidly compared to HLA-B27 
when expressed in HeLa cells (panel 5–6).
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